Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033668 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
A Phase 1 study of Atrophy, Geographic, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT02033668 is a Phase 1 study of Atrophy, Geographic that has completed, run by GlaxoSmithKline. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02033668, a Phase 1 study of Atrophy, Geographic, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles, and immunogenicity of GSK933776 following IM and SQ administration in healthy volunteers. Such alternate routes of administration may provide more options in the selection of an efficacious dose for subsequent development in patients with geographic atrophy. There will be four treatment arms in the study and participants will be assigned to 1 of 4 possible treatment arms in a 1:1:1:1 ratio. The planned number of evaluable participants for this study is 24 with 6 participants completing all critical assessments in each of the four treatment arms. The total duration of participation from screening to follow-up for Treatment Arms A, B and D (single dose of GSK933776), will be approximately 113 days and total duration for Treatment Arm C (repeat dose of GSK933776) will be approximately 134 days.
Conditions Studied
Interventions
- DRUG GSK933776 for SQ administration
- DRUG GSK933776 for IM administration
- DRUG GSK933776 for IV administration
Study Locations (1)
Kansas
- GSK Investigational Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-01-22 |
| Est. Completion | 2014-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02033668
The ClinicalTrials.gov registry entry for NCT02033668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrophy, Geographic appearing as the primary indexed condition, and to 3 interventions - of which GSK933776 for SQ administration is the first listed.
NCT02033668 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT02033668 about?
NCT02033668 is a clinical study titled "Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers". This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles, and immunogenicity of GSK933776 following IM and SQ administration in he...
What is the current status of trial NCT02033668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2014-01-22. Estimated completion is 2014-07-15.
What conditions does trial NCT02033668 study?
This clinical trial studies the following conditions: Atrophy, Geographic.
What interventions are being tested in trial NCT02033668?
The interventions under investigation include: GSK933776 for SQ administration (DRUG), GSK933776 for IM administration (DRUG), GSK933776 for IV administration (DRUG).
Who is sponsoring clinical trial NCT02033668?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02033668 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrophy, Geographic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.